Clinical Trials on Plasma

Total 4042 results

Assiut University

Unknown

Platelet Rich Plasma in Treatment of Melasma

Melasma | Platelet Rich Plasma

Egypt
University of Texas Southwestern Medical Center
Becton, Dickinson and Company

Completed

A Randomized Trial Examining Plasma Exchange Using the Becton Dickinson (BD) Catheter In an Outpatient Apheresis Unit (REPLACE)

Plasma Exchange

United States
Benedictine University

Unknown

Effects of Exercise and 5-HTP on Cortisol Levels

Plasma Cortisol

United States
Boston University

Completed

Evaluation of a Device That Separates Blood Cells From Serum/Plasma

Plasma Extraction

United States
AcelRx Pharmaceuticals, Inc.

Completed

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Plasma Concentrations

United States
AstraZeneca

Completed

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Rennes University Hospital

Completed

TPE in Rennes Hospital (COMPLASMA)

Therapeutic Plasma Exchange

France
PepsiCo Global R&D

Completed

Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers

Plasma Caffeine Concentration

United States
Nanyang Technological University

Completed

Nitrate and Power Output After Two Beetroot Juice Drinks

Blood Plasma Nitrite

Singapore
Cliniques universitaires Saint-Luc- Université...

Completed

IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.

Therapeutic Plasma Exchange

Belgium
Assiut University

Unknown

Effect of Platelet-Rich-Plasma in Spine Fusion

Platelet-Rich Plasma
B. Braun Melsungen AG

Completed

Safety Profile of Hydroxyethyl Starch

Plasma Volume Replacement

Malaysia, China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Completed

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
University of Southampton
Food Standards Agency, United Kingdom; Ocean Nutrition

Completed

Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition

Plasma Omega-3 Status

United Kingdom
Harrison, Theodore, M.D.

Unknown

Calculation of Platelet-rich Plasma Preparation Yield

Platelet-rich Plasma Production

Canada
FrieslandCampina
Wageningen University and Research

Completed

Dairy and Plant Amino Acid Uptake. An Explorative Study (DaPa)

Amino Acid Plasma Profile

Netherlands
Seoul National University Hospital

Completed

Effect of Tidal Volume Change on Pressure-based Prediction of Fluid Responsiveness in Children

Plasma Volume | Tidal Volume

Korea, Republic of
AstraZeneca

Completed

Explore the Performance of IntelliCap.

Pharmacokinetic Profile | Plasma Concentration

United Kingdom
Peterson, Noel, N.D.

Completed

Efficacy of Training in Manual Preparation of Platelet Rich Plasma

Platelet Rich Plasma Production

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects

Healthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Plasma Mycophenolic Acid (MPA) | Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)

United States
Ramsay Générale de Santé
European Clinical Trial Experts Network

Completed

Constitutive Study of a Serum Bank and Plasma Bank of Healthy Subjects Comparators to Dialysis Subjects (SPSSCD) (SPSSCD)

Dialysis | Serum Bank | Plasma Bank

France
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Healthy | Plasma Concentration of YM060

Japan
Chang Gung Memorial Hospital

Completed

Systemic Effects After Local Injection of Platelet-rich Plasma

Platelet Rich Plasma (PRP)

Taiwan
University of Virginia
The University of Queensland

Completed

Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

Plasma Concentration of Antibiotics

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
University of Exeter
Quorn

Completed

Protein Extrusion and Postprandial Amino Acid Handling (BABE)

Postprandial Plasma Amino Acid Availability

United Kingdom
Astellas Pharma Inc

Completed

A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets

Healthy | Plasma Concentration of ASP1941

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Healthy | Plasma Concentration of YM060

Japan
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation (PCL-2)

Plasma Cell Leukemia
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
University of Alabama at Birmingham

Completed

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

Therapeutic Plasma Exchange | Anticoagulant Therapy

United States
Alison Gernand
Penn State University

Completed

Cyclic Variation in Micronutrient Concentrations and Plasma Volume

Menstrual Cycle | Plasma Volume | Micronutrients

United States
University of Jordan
Nutritional Fundamentals for Health

Completed

Determination of Pharmacokinetics of Different Curcuminoids Preparations: Pilot Study

Plasma Levels of Different Curcuminoids Preparations

Jordan

Clinical Trials on Plasma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations